Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec:100 Suppl 2:75-83.
doi: 10.1016/s0001-7310(09)73382-4.

Keloid scarring: new treatments ahead

Affiliations
Review

Keloid scarring: new treatments ahead

Ulrich Mrowietz et al. Actas Dermosifiliogr. 2009 Dec.

Abstract

Keloid disease presents a healthcare challenge: patients suffer from pruritus, pain, inflammation, and cosmetic disfigurement. There is no single effective therapeutic regimen for keloids. Numerous treatment options have been described including occlusive dressings, compression therapy, intralesional steroid injections, laser and radiation therapy, cryosurgery, 5-fluorouracil, interferon, and imiquimod cream, but managing keloid disease still is a considerable problem for clinicians. Better understanding of the molecular mechanisms behind keloid disease led to the development of new promising therapies like the application of recombinant TGF-b3, interleukin 10, and imatinib mesylate. This review provides an overview of the existing therapeutic options for keloid disease and summarizes upcoming future therapies with a special focus on blocking the transforming growth factor-beta pathway.

PubMed Disclaimer